Changes in Helicobacter pylori Immunoglobulin G Levels and Gastric Mucosal Atrophy after Successful Eradication of Helicobacter pylori

Kim, Ji Hye; Lee, Joon Seop; Kwon, Yong Hwan; Nam, Su Youn; Jin, Sun

doi:10.7704/kjhugr.2019.19.3.174.e1

Cited by 2 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Previous study reported negative conversion rates of 35–62% at 1 year from H. pylori elimination. 25 , 26 , 28 , 29 It took 17.9 months for those with an intermediate level of antibody titer before eradication to convert to negative, and 42.8 months for those with a higher level. 30 Complete negative conversion was usually not observed within 1 year after eradication.…”

Section: Discussionmentioning

confidence: 99%

Long-term Response of <i>Helicobacter pylori</i> Antibody Titer After Eradication Treatment in Middle-aged Japanese: JPHC-NEXT Study

Tanaka

Goto

Yamagishi

et al. 2023

Journal of Epidemiology

View full text Add to dashboard Cite

Background: Helicobacter pylori (H. pylori) is an established causative factor of gastric cancer. Although the expansion of insurance coverage has led to an increase in the number of patients treated for H. pylori, the population impact of eradication treatment for H.pylori has been scarcely investigated. This study aimed to clarify the long-term responses of H. pylori antibody titer after eradication treatment using large scale cross-sectional data from the Japan Public Health Center-based Prospective Study for the Next Generation (JPHC-NEXT Study).Methods: A total of 55,282 Japanese participants aged 40 to 74 years residing in 16 areas provided blood samples between 2011 and 2016. From these, treated (n=6,276) and untreated subjects who were seropositive for H. pylori or had serological atrophy (n= 22,420) formed the study population (n=28,696). Seropositivity was defined as an anti-H. pylori IgG titer of ≥10 U/mL. Antibody level was compared among subjects according to self-reported treatment history as untreated, and treated for less than one year (<1Y), one to five years (1-5Y), and more than six years ago (6Y+).

show abstract

Section: Discussionmentioning

confidence: 99%

Long-term Response of <i>Helicobacter pylori</i> Antibody Titer After Eradication Treatment in Middle-aged Japanese: JPHC-NEXT Study

Tanaka

Goto

Yamagishi

et al. 2023

Journal of Epidemiology

View full text Add to dashboard Cite

show abstract

“…In several studies conducted on clinical factors related to recurrence, the patient's young age and a high δ value on the UBT performed to confirm eradication and the severity of dyspeptic symptoms were associated with recurrence. 18,19 In most cases of recrudescence, it comes from the initial false negative results of post-eradication testing. Because these studies were retrospective reviews, it is difficult to generalize recurrence trends to the entire population.…”

Section: F I G U R E 3 Eradication Outcomes In Patients With Recrudes...mentioning

confidence: 99%

Recurrence of Helicobacter pylori following successful eradication and clinical outcomes in Korean patients

Lim,

Kim,

Chung

2023

Helicobacter

View full text Add to dashboard Cite

Background/AimsHelicobacter pylori (H. pylori) infections can recur as either recrudescence or reinfection. At a time when the decline in the eradication rate is becoming evident, increases in the rate of recurrence are concerning. In addition, there are no guidelines for selecting an eradication regimen for H. pylori recurrence.Materials and MethodsA total of 996 H. pylori‐infected patients treated with proton‐pump inhibitor‐based triple eradication therapy between 2017 and 2022 were enrolled in the study, and successful eradication therapies were confirmed by the 13C‐urea breath test. When retested within 1 year after successful eradication, analysis related to recrudescence was performed, and when retested after 1 year, analysis related to reinfection was performed. We reviewed the medical records and treatment outcomes of patients with H. pylori reinfection after successful eradication.ResultsThe recrudescence rate was 3.9% (9/228), and the reinfection rate was 3.7% (36/970 person‐year). The frequency of reinfection reached 5.9% per person‐year within the first 24 months and 2.0%–2.4% per person‐year thereafter. In multivariate factor analysis, reinfection was significantly higher in patients with non‐ulcer dyspepsia (p < 0.01). At first‐line therapy for reinfection, the eradication rate of standard triple therapy (STT) was 50.0% (16/32). The eradication rate of second‐line bismuth quadruple therapy was 81.3% (13/16), and levofloxacin‐based rescue therapy was 66.7% (2/3).ConclusionRe‐treatment of patients with H. pylori reinfection with STT had limited efficacy. Prospective research is needed to determine whether patients with non‐ulcer dyspepsia are vulnerable to reinfection.

show abstract

Changes in Helicobacter pylori Immunoglobulin G Levels and Gastric Mucosal Atrophy after Successful Eradication of Helicobacter pylori

Cited by 2 publications

References 0 publications

Long-term Response of <i>Helicobacter pylori</i> Antibody Titer After Eradication Treatment in Middle-aged Japanese: JPHC-NEXT Study

Long-term Response of <i>Helicobacter pylori</i> Antibody Titer After Eradication Treatment in Middle-aged Japanese: JPHC-NEXT Study

Recurrence of Helicobacter pylori following successful eradication and clinical outcomes in Korean patients

Contact Info

Product

Resources

About